Rob was previously Senior Consultancy & Compliance Officer at Nerudia, sold to Imperial Brands in 2017, where he helped grow the Company into a global, science-led business, in a highly-regulated space. This included development of scientific and regulatory engagement platforms across Vape, Oral Nicotine, Heated Tobacco and CBD. Spending a period of time based in Washington D.C., Rob was responsible for developing the Company’s FDA multi-platform engagement strategy. During his time at Nerudia, Rob developed a close working relationship with Co-Founders David Newns and Chris Lord.

Prior to this, Rob headed up Corporate and Regulatory Affairs at US-based electronic cigarette company White Cloud, which he joined after five years at BAT as Group Head of Public Health and Scientific Affairs. At BAT, Rob led a team of industry-respected scientists focused on delivering the Company’s global external scientific engagement.

Before joining BAT in 2008, Rob spent over 20 years in the pharmaceutical sector working for AstraZeneca and SmithKline Beecham (GSK). During this time, Rob held several senior, international, commercial and scientific roles, including Global Commercial Director for Respiratory Products at AstraZeneca and General Manager and Area Director for Eastern European markets at SmithKline Beecham and AstraZeneca.

He has also held non-executive roles with several biotech start-up companies and regularly consults in both Commercial and Regulatory disciplines in the UK and Europe.

Rob is on the Advisory and Scientific Boards for Cannabis For Children (a US not-for-profit organisation), is an Advisory Board member for Blossom Genetics and is a Director and Board Member of AAN Medical and a member of the Medical Cannabis Clinicians Society.

An industrial chemist by training, Rob began his career working in the laboratories of Reckitt & Coleman, before moving into sales and marketing functions within Beecham’s UK. Throughout his global career Rob has spent over 13 years living in the USA, Sweden, Czech Republic and Estonia.